Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.44 |
| ▸ | FDPS | P14324 | 9/20 | 0.42 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912577 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL1116214 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL9204826 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL9210809 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL1263551 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL1669037 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL1115966 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL9214897 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL84154 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 | |
| SCHEMBL11804623 | 1.00 | TSHR (0.53) | TSHRTHRBGGPS1FDPSSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116554634-A | Flame-retardant anti-leakage lead-acid storage battery plastic shell and preparation method thereof | 安徽华腾再生金属科技有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-109824573-B | Method for synthesizing cyanoalkylindoline by N-allylaniline cyanoalkylation | 昆明学院 | 2022-05-10 | — | — | CN | claimed |
| CN-109912488-B | Method for synthesizing 3-alkyl indoline by alkylation of non-activated olefin under catalysis of copper | 昆明学院 | 2022-05-10 | — | — | CN | claimed |
| US-20240208899-A1 | POLYTHIOL COMPOSITION, OPTICAL POLYMERIZABLE COMPOSITION, AND OPTICAL PRODUCT | SK PUCORE CO., LTD. (KR) | 2024-06-27 | — | — | US | disclosed |
| WO-2024106985-A1 | XYLENE DIISOCYANATE COMPOSITION AND PREPARATION METHOD THEREFOR | 한화솔루션 주식회사 | 2024-05-23 | — | — | WO | disclosed |
| WO-2024048993-A1 | ISOCYANATE COMPOSITION | 한화솔루션 주식회사 | 2024-03-07 | — | — | WO | disclosed |
| US-20240067770-A1 | POLYTHIOL COMPOSITION AND OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME | SK PUCORE CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20240034829-A1 | POLYTHIOL COMPOSITION, OPTICAL COMPOSITION, AND OPTICAL PRODUCT | SK PUCORE CO., LTD. (KR) | 2024-02-01 | — | — | US | disclosed |
| US-20240034831-A1 | Process of preparing isocyanate compounds comprising non-chlorinated derivative and composition thereof | KIM, KEUN SIK (KR) | 2024-02-01 | — | — | US | disclosed |
| US-20240026063-A1 | XYLYLENE DIISOCYANATE COMPOSITION AND OPTICAL COMPOSITION COMPRISING SAME | SK PUCORE CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| US-20240002336-A1 | POLYTHIOL COMPOSITION, OPTICAL COMPOSITION, AND OPTICAL PRODUCT | SK PUCORE CO., LTD. (KR) | 2024-01-04 | — | — | US | disclosed |
| US-6410679-B1 | COMPLEX CONTAINING POLYOXYALKYLAENE GLYCOL AND QUATERNIZED COMPOUND | BIOSIL RESEARCH INSTITUTE | 2002-06-25 | — | — | US | disclosed |
| EP-1060161-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) | 2000-12-20 | — | — | EP | disclosed |
| US-5968492-A | SURFACTANTS FOR HAIR CONDITIONING USING AMINO ACIDS AND ALCOHOLS AND WASHING | AJINOMOTO CO., INC. (JP) | 1999-10-19 | — | — | US | disclosed |
| WO-1999044989-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) | 1999-09-10 | — | — | WO | disclosed |
| EP-0615741-B1 | Oil-in-water type emulsion composition | SHISEIDO CO LTD (JP) | 1999-07-07 | — | — | EP | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
| US-4051223-A | SELECTIVE, CALCIUM SEPARATION, HYDROGEN ION EXCHANGE RESIN | GENERAL MILLS CHEMICALS, INC. (US) | 1977-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240034829-A1 | POLYTHIOL COMPOSITION, OPTICAL COMPOSITION, AND OPTICAL PRODUCT | C9, PUF60, C5 | TSHR 4556/4885THRB 4391/4885GGPS1 1372/4885 |
| US-20240002336-A1 | POLYTHIOL COMPOSITION, OPTICAL COMPOSITION, AND OPTICAL PRODUCT | PARG, OSTC, SPECC1L | TSHR 3544/4885THRB 2407/4885GGPS1 1598/4885 |
| US-20240208899-A1 | POLYTHIOL COMPOSITION, OPTICAL POLYMERIZABLE COMPOSITION, AND OPTICAL PRODUCT | FHIT, PARG, OXTR | TSHR 2030/4885THRB 1480/4885GGPS1 3073/4885 |
| US-20240034831-A1 | Process of preparing isocyanate compounds comprising non-chlorinated derivative and composition thereof | IDH3A, DDT, CBR3 | TSHR 3692/4885THRB 4317/4885GGPS1 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.